Ignite Creation Date:
2025-12-25 @ 2:25 AM
Ignite Modification Date:
2026-05-13 @ 7:20 AM
Study NCT ID:
NCT00755534
Status:
TERMINATED
Last Update Posted:
2013-02-13
First Post:
2008-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
Sponsor:
Hellenic Oncology Research Group
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CT/05.31
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |